Tiny agents found in omega-3 could potentially be used to block the path of primary cancer tumors, preventing the advance to secondary-stage cancers according to pharmacy researchers at the University of Sydney.
Investigators in the Faculty of Pharmacy's Pharmacogenomics and Drug Development Group are using breast cancer tissue cells to gauge the blocking capacity of the omega-3 agents called epoxides on cancer cell movement.
Dr Michael Murray, Professor of Pharmogenetics at the university, says a major life-threatening consequence of malignant breast tumors is metastasis where the disease has spread to distant sites (or tissues) and at present there are no treatments.
He led his team to the discovery of the anti-metastatic actions of epoxides, which are produced within the body from omega-3 polyunsaturated fatty acids. The ground-breaking work has led Murray and his Drug Development Group deeper into the molecular structure of the omega-3 agents.
Professor Murray says:
"These agents are a bit like frontline soldiers blocking the assault of an invading army and now we want to advance our research which was published late last year and apply it to breast cancer cells."
"We know that epidemiological studies have reported that dietary intake of omega-3 polyunsaturated fatty acids including eicosapentaenoic and docosahexaenoic acids, decrease the risk of certain cancers. And many of us are including sources of omega-3 such as tuna and salmon in our diet as a precaution."
"The major objective of our new project is to speed the development of anti-metastatic agents based on omega-3 epoxides and trial their effectiveness in vivo on breast cancer tissue."
"Longer term we are aiming to develop a completely new class of anti-metastatic drugs designed to inhibit the spread of primary cancers," Murray says. . .View Full Article
"CPRX has a few programs in indications that are less crowded and do not have many successful treatment options." (11/26/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Michael Hay More >
"ATHX's MultiStem phase 2 data are going to be very important for investors if the trial is positive for patients." (11/26/13) Athersys Inc. - The Life Sciences Report Interview with Michael Hay More >
"We expect FDA approval in the near term—likely by the end of the year—for OCLS' Microcyn Hydrogel device." (11/26/13) Oculus Innovative Sciences Inc. - The Life Sciences Report Interview with Jocelyn August More >
Fatty Acids Fight Cancer Spread
Source: News Medical (4/9/12)
"Tiny agents found in omega-3 could potentially be used to block the path of primary cancer tumors, preventing the advance to secondary-stage cancers."
"CYTX's upcoming ATHENA clinical data will be a major catalyst for the company, giving confidence not only to investors but also to the physician community." (11/14/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >
"INO has extraordinary potential; I really want to see CEO Joseph Kim and Dave Weiner push this technology into the future." (10/24/13) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Patrick Cox More >
"CPRX is an emerging biotechnology company in the white hot space of orphan drug medicines." (11/7/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Scott Henry More >
"BDSI's buprenorphine product for chronic pain could be a $500M+/year revenue-generating drug if approved." (11/7/13) BioDelivery Sciences International Inc. - The Life Sciences Report Interview with Scott Henry More >